Conditions: Idiopathic Pulmonary Fibrosis
Keywords: IPF
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 325
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).

Detailed description:

Arms:
arm 1: BMS-986020, 600 mg tablets, by mouth, once daily, 26 weeks arm 2: BMS-986020, 600 mg tablets, by mouth, twice daily, 26 weeks arm 3: Placebo, 0 mg tablets, by mouth, twice daily, 26 weeks

Interventions: intervention 1: BMS-986020 intervention 2: Placebo matching with BMS-986020
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: